GS-441524 for FIP

What the evidence shows

Peer-reviewed clinical studies have reported favorable outcomes in many cats treated with GS-441524 for naturally occurring FIP. Research includes oral treatment studies and work involving effusive, non-effusive and neurological presentations.

Results from a study population cannot guarantee an outcome for an individual cat. Disease severity, presentation, concurrent illness, product quality and veterinary management can influence results.

FIP is not one uniform presentation

• Effusive FIP with fluid accumulation
• Non-effusive or dry FIP
• Ocular involvement
• Neurological involvement
• Mixed presentations

Monitoring is part of treatment

Veterinary follow-up helps assess clinical response, weight change and laboratory trends and can identify complications or alternative diagnoses. Website information should never be used to calculate or modify an individual cat’s treatment.

Access and regulatory status

Rules for prescribing, compounding, importing and supplying GS-441524 differ by jurisdiction. For example, the US FDA describes specific enforcement discretion for patient-specific veterinary compounding while also stating that compounded products remain unapproved drugs.